| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702715 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
Positive expression of immune checkpoint-associated molecules in tumor tissues could be useful prognosticators in patients with mRCC receiving TKIs as first-line systemic therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Takuto M.D., Hideaki M.D., Ph.D., Masato M.D., Ph.D.,